New players in haemostasis and thrombosis

Julia E. Geddings; Nigel Mackman

doi:10.1160/TH13-10-0812

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(04): 570-574
DOI: 10.1160/TH13-10-0812

Theme Issue Article

Schattauer GmbH

New players in haemostasis and thrombosis

Julia E. Geddings

¹Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

,

Nigel Mackman

¹Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

²UNC McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina, USA

³Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

› Institutsangaben

Abstract

Summary

The blood coagulation cascade is essential for haemostasis, but excessive activation can cause thrombosis. Importantly, recent studies have identified factors that contribute to thrombosis but not haemostasis. These include factor XII (FXII), tissue factor-positive microparticles (MPs) and neutrophil extracellular traps (NETs). Studies have shown that FXII plays a role in thrombosis but not haemostasis. FXII is activated in vivo by a variety of negatively-charged polyphosphates, which include extracellular RNA, DNA and inorganic polyphosphate (PolyP) that are released during cell damage and infection. These findings have led to the development of nucleic acid-binding polymers as a new class of anticoagulant drug. Other studies have analysed the role of MPs in experimental thrombosis. MPs are small membrane vesicles released from activated or apoptotic cells. We and others have found that tissue factor-positive MPs enhance thrombosis in mouse models and are elevated in the plasma of pancreatic cancer patients. Finally, NETs have been shown to contribute to experimental venous thrombosis in mouse models and are present in human thrombi. NETs are composed of chromatin fibers that are released from neutrophils undergoing cell death. NETs can capture platelets and increase fibrin deposition. The recent advances in our understanding of the factors contributing to thrombosis in animal models provide new opportunities for the development of safer anticoagulant drugs.

Keywords

Coagulation factors - deep-vein thrombosis - arterial thrombosis - microparticles - thrombosis

Volltext

Referenzen

References
1 Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which?. Where? When? Arterioscler Thromb Vasc Biol 2009; 29: 1989-1996.
2 Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis.. Arterioscler Thromb Vasc Biol 2007; 27: 2507-2513.
3 Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets.. Current opinion in hematology 2011; 18: 349-355.
4 Konings J, Govers-Riemslag JW, Philippou H. et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin.. Blood 2011; 118: 3942-3951.
5 Renne T, Pozgajova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII.. J Exp Med 2005; 202: 271-281.
6 Kannemeier C, Shibamiya A, Nakazawa F. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
7 Muller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflam-matory and procoagulant mediators in vivo.. Cell 2009; 139: 1143-1156.
8 Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis.. Arterioscler Thromb Vasc Biol 2012; 32: 1777-1783.
9 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with haemostasis.. J Exp Med 2006; 203: 513-518.
10 Xu Y, Cai TQ, Castriota G. et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.. Thromb Haemost 2014; 111: 694-704.
11 Hagedorn I, Schmidbauer S, Pleines I. et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding.. Circulation 2010; 121: 1510-1517.
12 Yamashita A, Nishihira K, Kitazawa T. et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery.. J Thromb Haemost 2006; 4: 1496-1501.
13 Schumacher WA, Seiler SE, Steinbacher TE. et al. Antithrombotic and haemostatic effects of a small molecule factor XIa inhibitor in rats.. Eur J Pharmacol 2007; 570: 167-174.
14 Tucker EI, Marzec UM, White TC. et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.. Blood 2009; 113: 936-944.
15 Crosby JR, Marzec U, Revenko AS. et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.. Arterioscler Thromb Vasc Biol 2013; 33: 1670-1678.
16 Leung PY, Hurst S, Berny-Lang MA. et al. Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice.. Translat Stroke Res 2012; 3: 381-389.
17 Lowenberg EC, Meijers JC, Monia BP. et al. Coagulation factor XI as a novel target for antithrombotic treatment.. J Thromb Haemost 2010; 8: 2349-2357.
18 Zhang H, Lowenberg EC, Crosby JR. et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.. Blood 2010; 116: 4684-4692.
19 Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.. Blood 2012; 119: 5972-5979.
20 Smith SA, Mutch NJ, Baskar D. et al. Polyphosphate modulates blood coagulation and fibrinolysis.. Proc Natl Acad Sci USA 2006; 103: 903-908.
21 Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure.. Blood 2008; 112: 2810-2816.
22 Smith SA, Choi SH, Davis-Harrison R. et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size.. Blood 2010; 116: 4353-4359.
23 Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent.. J Thromb Haemost 2008; 6: 1750-1756.
24 Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin.. Blood 2011; 118: 6963-6970.
25 Faxalv L, Boknas N, Strom JO. et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII.. Blood 2013; 29: 29.
26 Nickel KF, Spronk HM, Mutch NJ. et al. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation.. Blood 2013; 122: 3847-3849.
27 Morrissey JH. S.A.S. Comment on Fzxalv. et al. “Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII”.. Blood. 2013 e-Letter online, August 26, 2013.
28 Ghosh S, Shukla D, Suman K. et al. Inositol hexakisphosphate kinase 1 maintains haemostasis in mice by regulating platelet polyphosphate levels.. Blood 2013; 122: 1478-1486.
29 Jain S, Pitoc GA, Holl EK. et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding.. Proc Natl Acad Sci USA 2012; 109: 12938-12943.
30 Smith SA, Choi SH, Collins JN. et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation.. Blood 2012; 120: 5103-5110.
31 Gyorgy B, Szabo TG, Pasztoi M. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.. Cell Mol Life Sci 2011; 68: 2667-2688.
32 D’Souza-Schorey C, Clancy JW. Tumour-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.. Genes Dev 2012; 26: 1287-1299.
33 Owens 3rd AP, Mackman N. Microparticles in haemostasis and thrombosis.. Circ Res 2011; 108: 1284-1297.
34 Wolf P. The nature and significance of platelet products in human plasma.. Br J Haematol 1967; 13: 269-288.
35 Burnier L, Fontana P, Kwak BR. et al. Cell-derived microparticles in haemostasis and vascular medicine.. Thromb Haemost 2009; 101: 439-451.
36 Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles.. Semin Thromb Haemost 2010; 36: 865-875.
37 Ramacciotti E, Hawley AE, Wrobleski SK. et al. Proteomics of microparticles after deep venous thrombosis.. Thromb Res 2010; 125: e269-274.
38 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in haemostasis and thrombosis.. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.
39 Mackman N. New insights into the mechanisms of venous thrombosis.. J Clin Invest 2012; 122: 2331-2336.
40 Aleman MM, Gardiner C, Harrison P. et al. Differential contributions of mono-cyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability.. J Thromb Haemost 2011; 9: 2251-2261.
41 Owens 3rd AP, Mackman N. Tissue factor and thrombosis: The clot starts here.. Thromb Haemost 2010; 104: 432-439.
42 Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange.. Circ Res 2010; 107: 1047-1057.
43 Morrissey JH, Tajkhorshid E, Rienstra CM. Nanoscale studies of protein-membrane interactions in blood clotting.. J Thromb Haemost 2011; 9 (Suppl. 01) 162-167.
44 Hrachovinova I, Cambien B, Hafezi-Moghadam A. et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct haemostasis in a mouse model of haemophilia A.. Nat Med 2003; 9: 1020-1025.
45 Jy W, Johansen ME, Bidot Jr C. et al. Red cell-derived microparticles (RMP) as haemostatic agent.. Thromb Haemost 2013; 110: 751-760.
46 Berckmans RJ, Nieuwland R, Boing AN. et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.. Thromb Haemost 2001; 85: 639-646.
47 Biro E, Sturk-Maquelin KN, Vogel GM. et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.. J Thromb Haemost 2003; 1: 2561-2568.
48 Thomas GM, Panicot-Dubois L, Lacroix R. et al. Cancer cell-derived micropar-ticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.. J Exp Med 2009; 206: 1913-1927.
49 Wang JG, Geddings JE, Aleman MM. et al. Tumour-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.. Blood 2012; 119: 5543-5552.
50 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.. N Engl J Med 2009; 360: 1851-1861.
51 Pai M, Evans NS, Shah SJ. et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies.. Thromb Res 2011; 128: 422-430.
52 Owens 3rd AP, Passam FH, Antoniak S. et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.. J Clin Invest 2012; 122: 558-568.
53 Geddings JE, Mackman N. Tumour-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.. Blood 2013; 122: 1873-1880.
54 Myers Jr. DD, Rectenwald JE, Bedard PW. et al. Decreased venous thrombosis with an oral inhibitor of P selectin.. J Vasc Surg 2005; 42: 329-336.
55 Meier TR, Myers Jr. DD, Wrobleski SK. et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagu- lation.. Thromb Haemost 2008; 99: 343-351.
56 Ramacciotti E, Myers Jr. DD, Wrobleski SK. et al. P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.. Thromb Res 2010; 125: e138-142.
57 Fuchs TA, Abed U, Goosmann C. et al. Novel cell death program leads to neut-rophil extracellular traps.. J Cell Biol 2007; 176: 231-241.
58 Brinkmann V, Reichard U, Goosmann C. et al. Neutrophil extracellular traps kill bacteria.. Science 2004; 303: 1532-1535.
59 Yipp BG, Kubes P. NETosis: how vital is it?. Blood 2013; 5: 5.
60 Pilsczek FH, Salina D, Poon KK. et al. A novel mechanism of rapid nuclear neut-rophil extracellular trap formation in response to Staphylococcus aureus.. J Immunol 2010; 185: 7413-7425.
61 Yipp BG, Petri B, Salina D. et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo.. Nat Med 2012; 18: 1386-1393.
62 Yousefi S, Mihalache C, Kozlowski E. et al. Viable neutrophils release mitochon-drial DNA to form neutrophil extracellular traps.. Cell Death Differ 2009; 16: 1438-1444.
63 von Bruhl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.. J Exp Med 2012; 209: 819-835.
64 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis.. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
65 Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice.. Blood 2011; 118: 3708-3714.
66 Massberg S, Grahl L, von Bruehl ML. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.. Nat Med 2010; 16: 887-896.
67 Martinod K, Demers M, Fuchs TA. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice.. Proc Natl Acad Sci USA 2013; 110: 8674-8679.
68 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice.. J Thromb Haemost 2012; 10: 136-144.
69 Saffarzadeh M, Juenemann C, Queisser MA. et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of hi-stones.. PloS one 2012; 7: e32366.
70 Fuchs TA, Kremer Hovinga JA, Schatzberg D. et al. Circulating DNA and mye-loperoxidase indicate disease activity in patients with thrombotic microangio-pathies.. Blood 2012; 120: 1157-1164.
71 Diaz JA, Fuchs TA, Jackson TO. et al. Plasma DNA is Elevated in Patients with Deep Vein Thrombosis.. J Vasc Surg Ven Lymph Dis 2013; 1: 341-348.
72 van Montfoort ML, Stephan F, Lauw MN. et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis.. Arterioscler Thromb Vasc Biol 2013; 33: 147-151.
73 de Boer OJ, Li X, Teeling P. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction.. Thromb Haemost 2013; 109: 290-297.